Tofacitinib Citrate Uses and Mechanism of Action

2025-08-12

Tofacitinib citrate is an innovative Janus kinase (JAK) inhibitor that has revolutionized the treatment of several autoimmune conditions. This comprehensive guide explores the clinical applications, pharmacological mechanism, dosage forms, and safety profile of Tofacitinib citrate, providing healthcare professionals with essential information about this breakthrough medication developed by Run'an Pharmaceutical.

Tofacitinib Citrate

Clinical Applications of Tofacitinib Citrate

Tofacitinib citrate is FDA-approved for multiple therapeutic indications with proven efficacy in:

1. Rheumatoid Arthritis (RA)

    Moderate to severe active RA in adults

    Methotrexate combination or monotherapy

    Reduces joint swelling and progression of structural damage

2. Psoriatic Arthritis (PsA)

    Active PsA in patients with inadequate response to DMARDs

    Improves enthesitis and dactylitis

3. Ulcerative Colitis (UC)

    Moderate to severe active UC

    Induction and maintenance of remission

4. Other Investigational Uses

    Ankylosing spondylitis

    Alopecia areata

    Juvenile idiopathic arthritis

Indication Dosage Form Recommended Dose Treatment Duration
Rheumatoid Arthritis Tablet (5mg) 5mg twice daily Long-term
Psoriatic Arthritis Tablet (5mg) 5mg twice daily Long-term
Ulcerative Colitis Extended-release (11mg) 11mg once daily Induction: 8 weeks

Pharmacological Mechanism of Action

Tofacitinib citrate exerts its therapeutic effects through:

JAK-STAT Pathway Inhibition

    Selective inhibition of JAK1 and JAK3

    Modulation of cytokine signaling (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21)

    Reduction of inflammatory mediators

Immunomodulatory Effects

    Decreases circulating CD16+/CD56+ NK cells

    Reduces serum C-reactive protein (CRP) levels

    Lowers matrix metalloproteinase (MMP) levels

Cellular Impact
Cell Type Effect Clinical Outcome
T Cells Reduced proliferation Decreased inflammation
B Cells Limited activation Lower autoantibody production
Macrophages Inhibited activation Reduced tissue damage

Safety Profile and Risk Management

Common Adverse Effects

    Upper respiratory tract infections (15-20%)

    Headache (4-7%)

    Diarrhea (3-5%)

    Increased LDL cholesterol (10-15%)

Serious Risks

✔ Herpes zoster reactivation
✔ Thromboembolic events
✔ Lymphoma and other malignancies
✔ Gastrointestinal perforations

Why Choose Run'an Pharmaceutical's Tofacitinib Citrate?

✔ cGMP-certified manufacturing facilities
✔ Strict quality control exceeding pharmacopeial standards
✔ Comprehensive stability studies
✔ Global regulatory compliance (FDA, EMA, PMDA)
✔ Competitive pricing for healthcare systems

For product information, clinical data, or partnership opportunities:

As the Chief Scientific Officer at Run'an Pharmaceutical with 20 years of experience in immunomodulatory therapies, I personally guarantee the quality and efficacy of our Tofacitinib citrate formulations. Contact our medical affairs team today to discuss how we can support your therapeutic needs.

    No. 12, Zhangma Road, Salt Chemical New Materials Industrial Park
    wangjing@ctqjph.com
    +86-13646196320
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept